• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Angiodynamics Inc (NQ: ANGO )

    6.680 UNCHANGED
    Streaming Delayed Price Updated: 3:12 PM EST, Nov 4, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Angiodynamics Inc

    < Previous 1 2 3 Next >
    AngioDynamics and University College London Hospital Launch International Multi-Center Study to Assess Long Term Effects of Treatment with The NanoKnife® System
    From AngioDynamics, Inc.
    Via Business Wire
    AngioDynamics Announces American Medical Association’s CPT® Editorial Panel Grants Category I CPT® for Irreversible Electroporation (IRE) in Prostate and Liver
    From AngioDynamics, Inc.
    Via Business Wire
    AngioDynamics Reports Fiscal Year 2025 First Quarter Financial Results
    From AngioDynamics, Inc.
    Via Business Wire
    AngioDynamics Initiates RECOVER-AV Clinical Trial Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism and Long-Term Functional Outcomes
    From AngioDynamics, Inc.
    Via Business Wire
    AngioDynamics to Report Fiscal 2025 First Quarter Financial Results on October 3, 2024
    From AngioDynamics, Inc.
    Via Business Wire
    AngioDynamics Announces CE Mark Approval in Europe for the Auryon System
    From AngioDynamics, Inc.
    Via Business Wire
    AngioDynamics to Participate in Upcoming Investor Conferences
    From AngioDynamics, Inc.
    Via Business Wire
    AngioDynamics Reports Fiscal Year 2024 Fourth Quarter and Full-Year Financial Results
    From AngioDynamics, Inc.
    Via Business Wire
    AngioDynamics to Report Fiscal 2024 Fourth Quarter and Full-Year Financial Results on July 16, 2024
    From AngioDynamics, Inc.
    Via Business Wire
    AngioDynamics Announces CE Mark Approval in Europe for AlphaVac F18⁸⁵ System
    From AngioDynamics, Inc.
    Via Business Wire
    AngioDynamics’ APEX-AV Trial Results Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism Presented at SCAI 2024 Scientific Sessions
    From AngioDynamics, Inc.
    Via Business Wire
    AngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results; Updates Fiscal Year 2024 Guidance to Reflect Asset Divestiture
    From AngioDynamics, Inc.
    Via Business Wire
    AngioDynamics Receives 510(k) Clearance for AlphaVac F1885 System in Treatment of PE
    From AngioDynamics, Inc.
    Via Business Wire
    AngioDynamics Announces Settlement of All Patent Litigation with C.R. Bard, Inc.
    From AngioDynamics, Inc.
    Via Business Wire
    AngioDynamics to Report Fiscal 2024 Third Quarter Financial Results on April 4, 2024
    From AngioDynamics, Inc.
    Via Business Wire
    AngioDynamics to Participate in a Fireside Chat at the Oppenheimer Virtual Healthcare MedTech & Services Conference
    From AngioDynamics, Inc.
    Via Business Wire
    AngioDynamics Announces Sale of PICC and Midline Product Portfolios to Spectrum Vascular for $45 Million
    From AngioDynamics, Inc.
    Via Business Wire
    AngioDynamics Announces FDA 510(k) Clearance of Auryon XL Radial Access Catheter to Treat Peripheral Arterial Disease
    From AngioDynamics, Inc.
    Via Business Wire
    AngioDynamics Reports Fiscal Year 2024 Second Quarter Financial Results; Revises Fiscal Year 2024 Guidance
    From AngioDynamics, Inc.
    Via Business Wire
    AngioDynamics to Present at the J.P. Morgan Healthcare Conference
    From AngioDynamics, Inc.
    Via Business Wire
    AngioDynamics to Report Fiscal 2024 Second Quarter Financial Results on January 5, 2024
    From AngioDynamics, Inc.
    Via Business Wire
    AngioDynamics Completes Patient Enrollment in APEX-AV Study Assessing AlphaVac F1885 System in Treatment of Pulmonary Embolism
    From AngioDynamics, Inc.
    Via Business Wire
    AngioDynamics Reports Fiscal Year 2024 First Quarter Financial Results; Reaffirms Fiscal Year 2024 Guidance
    From AngioDynamics, Inc.
    Via Business Wire
    AngioDynamics to Report Fiscal 2024 First Quarter Financial Results on October 4, 2023
    From AngioDynamics, Inc.
    Via Business Wire
    AngioDynamics Receives FDA Breakthrough Device Designation for the AngioVac System for the Non-Surgical Removal of Right Heart Vegetation
    From AngioDynamics, Inc.
    Via Business Wire
    AngioDynamics Completes Enrollment for PRESERVE Clinical Study
    From AngioDynamics, Inc.
    Via Business Wire
    AngioDynamics to Participate in a Fireside Chat at the Canaccord Genuity Growth Conference
    From AngioDynamics, Inc.
    Via Business Wire
    AngioDynamics Announces Addition of Lorinda Burgess to Board of Directors
    From AngioDynamics, Inc.
    Via Business Wire
    AngioDynamics Reports Fiscal Year 2023 Fourth Quarter and Full-Year Financial Results; Issues Fiscal Year 2024 Guidance
    From AngioDynamics, Inc.
    Via Business Wire
    AngioDynamics to Report Fiscal 2023 Fourth Quarter and Full-Year Financial Results on July 12, 2023
    From AngioDynamics, Inc.
    Via Business Wire
    < Previous 1 2 3 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.